Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

PRIMARY OBJECTIVES:

I. To determine recommended phase II dose for oral ONC201 (Akt/ERK inhibitor ONC201) in patients with relapsed/refractory lymphomas. (Phase I) II. To identify toxicities associated with oral ONC201 in patients with relapsed/refractory lymphomas. (Phase I) III. To determine the objective response rate to ONC201 in patients with relapsed/refractory lymphomas. (Phase II)

SECONDARY OBJECTIVES:

I. To determine the pharmacokinetics (PK) of oral ONC201 following administration. (Phase I) II. To observe the anti-tumor effects of oral ONC201, if any occur, in patients with relapsed/refractory lymphomas. (Phase I) III. Confirm tolerability of recommended phase II dose. (Phase II) IV. Assess clinical outcomes associated with ONC201 treatment in patients with relapsed/refractory lymphomas. (Phase II) V. Correlate clinical outcome with tumor and serum biomarkers. (Phase II)

OUTLINE: This is a phase I, dose-escalation study followed by a phase II study.

Patients receive Akt/ERK inhibitor ONC201 orally (PO) on day 1 of every cycle or day 1 of every week. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months.

• Akt/ERK Inhibitor ONC201 (Drug), also known as ONC201, TIC10: Given PO
• Laboratory Biomarker Analysis (Other): Correlative studies
• Pharmacological Study (Other): Correlative studies

Primary outcomes

• Recommended Phase 2 Dose (RP2D) (Phase I) [21 days]
• Number of Participants With Overall Response Rate (Phase 1 and 2) [Up to 63 days (first 3 courses)]: Defined as either progressive disease or stable disease observed assessed by the Revised International Workshop Standardization Response Criteria for non-Hodgkin lymphoma.

Secondary outcomes

• Overall Survival (OS) [every 3 months for 1 year, then every 6 months, up to 3 years]: Overall survival is the time in months from start of study treatment to date of death due to any cause.
• Progression-free Survival (PFS)- (Phase 2) [every 3 months for 1 year, then every 6 months, up to 6 years]: Progression free survival is defined as time in weeks from start of study treatment to first documentation of objective tumor progression or up to death due to any cause, whichever occurs first.

Sex: All, ages: 18 Years to any

Inclusion Criteria:

* Phase 1 and Phase 2: confirmed diagnosis of previously treated relapsed and/or refractory lymphoma; patients with central nervous system (CNS) lymphoma are included
* Patient with leukemia phase (peripheral blood involvement), CNS lymphoma \[including cerebrospinal fluid (CSF)-only disease\], non-measurable disease, gastrointestinal (GI) mantle cell lymphoma (MCL), or bone marrow (BM) MCL are also eligible; gastrointestinal or bone marrow or spleen only patients are allowable and will be analyzed separately
* All adverse events related to prior therapies (chemotherapy, radiotherapy, and/or surgery) must be resolved to =< grade 1, except for alopecia
* Patients must be willing to receive transfusions of blood products
* Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less
* Serum creatinine < 2.0 mg/dl
* Serum bilirubin < 1.5 mg/dl
* Platelet count > 50,000/mm\^3
* Absolute neutrophil count (ANC) > 1,000/mm\^3
* Alanine aminotransferase (ALT), or aspartate aminotransferase (AST) < 2 x upper limit of normal or < 5 x upper limit of normal if hepatic metastases are present
* Willing and able to participate in all study related procedures and therapy including swallowing capsules without difficulty
* Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test and must be willing to use acceptable methods of birth control during the study and for 90 days after the last dose of study treatment; acceptable methods of birth control include condoms with birth control foam, birth control pills, implantable or injectable birth control, birth control patch, intrauterine device (IUD), or diaphragm with spermicidal gel; male patients must use an effective barrier method of contraception (i.e. , condoms with birth control foam or diaphragm with spermicidal gel) during the study and for 90 days following the last dose of study treatment if sexually active with a female of childbearing potential; contraception must be in place at least 2 weeks prior to initiating study treatment; a female of childbearing potential is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
* Patient must be English-speaking \[MD Anderson Symptom Inventory (MDASI) completion only\]

Exclusion Criteria:

* Any serious medical condition including but not limited to, uncontrolled hypertension, uncontrolled diabetes mellitus, uncontrolled infection, active/symptomatic coronary artery disease, chronic obstructive pulmonary disease (COPD), renal failure, active hemorrhage, or psychiatric illness that, in the investigators opinion places the patient at unacceptable risk or would prevent the subject from signing the informed consent form
* Pregnant or breast feeding females
* Use of any standard/experimental anti-lymphoma drug therapy, including steroids (dexamethasone dose >= 4 mg/day or prednisone >= 20 mg/day), within 3 weeks of initiation of the study or use of any experimental non-drug therapy (e.g., donor leukocyte/mononuclear cell infusions) within 56 days of initiation of the study drug treatment; hydroxyurea is permitted up to 24 hours before the first dose of study drug in patients with rapidly-proliferating disease
* Prior allogeneic stem cell transplant (SCT) within 16 weeks or autologous SCT within 8 weeks of initiation of therapy (patients that require immunosuppressive therapy are not eligible within 60 days of therapy)
* History of human immunodeficiency virus (HIV) infection; patients with active hepatitis B infection (not including patients with prior hepatitis B vaccination; or positive serum hepatitis B antibody); hepatitis C infection is allowed as long as there is no active disease and is cleared by GI consultation; HIV screening is not required for this study
* Significant neuropathy (grades 3-4, or grade 2 with pain) within 14 days prior to enrollment
* Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel or ulcerative colitis, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction, or any other gastrointestinal condition that could interfere with the absorption and metabolism of ONC201
* Major surgery within 4 weeks of initiation of therapy
* The patient has a prior or concurrent malignancy that in the opinion of the investigator, presents a greater risk to the patient's health and survival, than of the MCL, within the subsequent 6 months at the time of consent; investigator discretion is allowed
* Patients with New York Heart Association (NYHA) class III and IV heart failure, myocardial infarction in the preceding 6 months, and significant conduction abnormalities, including but not limited to second (2nd) degree atrioventricular (AV) block type II, third (3rd) degree block, QT prolongation (corrected QT \[QTc\] > 500 msec), sick sinus syndrome, ventricular tachycardia, symptomatic bradycardia (heart rate < 50 beats per minute \[bpm\]), hypotension, light headedness and syncope; patients with active atrial fibrillation will be excluded; the protocol excludes patients who have within the past year had a stent and by recommendation of their cardiologist need to stay on anticoagulants such as warfarin equivalent vitamin K antagonist
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to ONC201 or its excipients
* Acute infection requiring treatment (systemic antibiotics, antivirals, or antifungals) within 14 days prior to initiation of study
* Active alcoholism or use of recreational drug (evaluated by history taking)

Participant flow

Outcome results

• Recommended Phase 2 Dose (RP2D) (Phase I) (Primary), Number, mg: ONC201 125 mg 125
• Number of Participants With Overall Response Rate (Phase 1 and 2) (Primary), Count of participants, Participants: ONC201 125 mg 3; ONC201 250 mg 1; ONC201 625 mg 3
• Overall Survival (OS) (Secondary), Median, months: ONC201 125 mg 29 (1 to 30); ONC201 250 mg 15 (1 to 30); ONC201 625 mg 24 (1 to 48)
• Progression-free Survival (PFS)- (Phase 2) (Secondary), Median, weeks: ONC201 625 mg 5 (1 to 10)

Adverse events

Time frame: From the first dose through every 3 months after the last dose of study medication, up to 1 year.

Serious adverse events by term

Other adverse events by term

23 more terms not shown.

• Study Protocol and Statistical Analysis Plan (PDF, 2018-11-13)

• Luhua (Michael) Wang, Principal investigator, M.D. Anderson Cancer Center